<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d93" origId="Drotrecogin alfa"><sentence id="DrugDDI.d93.s0" origId="s0" text="Drug interaction studies with Xigris have not been performed in patients with severe sepsis."><entity id="DrugDDI.d93.s0.e0" origId="s0.p2" charOffset="30-36" type="drug" text="Xigris"/></sentence><sentence id="DrugDDI.d93.s1" origId="s1" text="However, since there is an increased risk of bleeding with Xigris, caution should be employed when Xigris is used with other drugs that affect hemostasis."><entity id="DrugDDI.d93.s1.e0" origId="s1.p15" charOffset="59-65" type="drug" text="Xigris"/><entity id="DrugDDI.d93.s1.e1" origId="s1.p21" charOffset="99-105" type="drug" text="Xigris"/><entity id="DrugDDI.d93.s1.e2" origId="s1.p24" charOffset="125-130" type="drug" text="drugs"/><pair id="DrugDDI.d93.s1.p0" e1="DrugDDI.d93.s1.e0" e2="DrugDDI.d93.s1.e1" interaction="?"/><pair id="DrugDDI.d93.s1.p1" e1="DrugDDI.d93.s1.e0" e2="DrugDDI.d93.s1.e2" interaction="?"/><pair id="DrugDDI.d93.s1.p2" e1="DrugDDI.d93.s1.e1" e2="DrugDDI.d93.s1.e2" interaction="?"/></sentence><sentence id="DrugDDI.d93.s2" origId="s2" text="Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin (unfractionated heparin up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products."><entity id="DrugDDI.d93.s2.e0" origId="s2.p33" charOffset="93-100" type="drug" text="heparin"/><entity id="DrugDDI.d93.s2.e1" origId="s2.p35" charOffset="102-124" type="drug" text="unfractionated heparin"/><entity id="DrugDDI.d93.s2.e2" origId="s2.p40" charOffset="152-164" type="drug" text="prophylactic"/><entity id="DrugDDI.d93.s2.e3" origId="s2.p41" charOffset="174-203" type="drug" text="low molecular weight heparins"/><pair id="DrugDDI.d93.s2.p0" e1="DrugDDI.d93.s2.e0" e2="DrugDDI.d93.s2.e1" interaction="?"/><pair id="DrugDDI.d93.s2.p1" e1="DrugDDI.d93.s2.e0" e2="DrugDDI.d93.s2.e2" interaction="?"/><pair id="DrugDDI.d93.s2.p2" e1="DrugDDI.d93.s2.e0" e2="DrugDDI.d93.s2.e3" interaction="?"/><pair id="DrugDDI.d93.s2.p3" e1="DrugDDI.d93.s2.e1" e2="DrugDDI.d93.s2.e2" interaction="?"/><pair id="DrugDDI.d93.s2.p4" e1="DrugDDI.d93.s2.e1" e2="DrugDDI.d93.s2.e3" interaction="?"/><pair id="DrugDDI.d93.s2.p5" e1="DrugDDI.d93.s2.e2" e2="DrugDDI.d93.s2.e3" interaction="?"/></sentence><sentence id="DrugDDI.d93.s3" origId="s3" text="Concomitant use of prophylactic low dose heparin did not appear to affect safety, however, its effects on the efficacy of Xigris have not been evaluated in an adequate and well-controlled clinical trial."><entity id="DrugDDI.d93.s3.e0" origId="s3.p47" charOffset="41-48" type="drug" text="heparin"/><entity id="DrugDDI.d93.s3.e1" origId="s3.p57" charOffset="122-128" type="drug" text="Xigris"/><pair id="DrugDDI.d93.s3.p0" e1="DrugDDI.d93.s3.e0" e2="DrugDDI.d93.s3.e1" interaction="?"/></sentence><sentence id="DrugDDI.d93.s4" origId="s4" text="Drug/Laboratory Test Interaction Because Xigris may affect the APTT assay, Xigris present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII, IX, and XI assays)."><entity id="DrugDDI.d93.s4.e0" origId="s4.p65" charOffset="0-4" type="drug" text="Drug"/><entity id="DrugDDI.d93.s4.e1" origId="s4.p68" charOffset="41-47" type="drug" text="Xigris"/><entity id="DrugDDI.d93.s4.e2" origId="s4.p72" charOffset="75-81" type="drug" text="Xigris"/><entity id="DrugDDI.d93.s4.e3" origId="s4.p81" charOffset="183-194" type="drug" text="factor VIII"/><pair id="DrugDDI.d93.s4.p0" e1="DrugDDI.d93.s4.e0" e2="DrugDDI.d93.s4.e1" interaction="?"/><pair id="DrugDDI.d93.s4.p1" e1="DrugDDI.d93.s4.e0" e2="DrugDDI.d93.s4.e2" interaction="?"/><pair id="DrugDDI.d93.s4.p2" e1="DrugDDI.d93.s4.e0" e2="DrugDDI.d93.s4.e3" interaction="?"/><pair id="DrugDDI.d93.s4.p3" e1="DrugDDI.d93.s4.e1" e2="DrugDDI.d93.s4.e2" interaction="?"/><pair id="DrugDDI.d93.s4.p4" e1="DrugDDI.d93.s4.e1" e2="DrugDDI.d93.s4.e3" interaction="?"/><pair id="DrugDDI.d93.s4.p5" e1="DrugDDI.d93.s4.e2" e2="DrugDDI.d93.s4.e3" interaction="?"/></sentence><sentence id="DrugDDI.d93.s5" origId="s5" text="This interference may result in an apparent factor concentration that is lower than the true concentration."/><sentence id="DrugDDI.d93.s6" origId="s6" text="Xigris present in plasma samples does not interfere with one-stage factor assays based on the PT (such as factor II, V, VII, and X assays)."><entity id="DrugDDI.d93.s6.e0" origId="s6.p94" charOffset="0-6" type="drug" text="Xigris"/><entity id="DrugDDI.d93.s6.e1" origId="s6.p103" charOffset="106-115" type="drug" text="factor II"/><pair id="DrugDDI.d93.s6.p0" e1="DrugDDI.d93.s6.e0" e2="DrugDDI.d93.s6.e1" interaction="?"/></sentence></document>